Sartorius Stedim Biotech has partnered with Nanotein Technologies in a deal that involves Sartorius investing up to $3 million in a minority stake in Nanotein Technologies. This investment aims to support the commercialization and joint development of solutions leveraging Nanotein’s NanoSpark® platform. As part of an exclusive distribution agreement, Sartorius Stedim Biotech will globally offer Nanotein’s flagship products: the NanoSpark STEM-T Soluble T Cell Activator and NanoSpark GROW-NK Soluble Activator. These reagents are specifically designed to enhance the expansion and quantity of T cells and natural killer (NK) cells, crucial immune cell types utilized in various cell therapy applications like CAR-T and NK-based cancer therapies.
The key to developing effective cell therapies lies in activating immune cells to stimulate expansion and produce a large quantity of high-quality cells. During this process, developers often encounter challenges such as the need for feeder cells or inconsistent yields. Nanotein’s soluble activators aim to address these challenges by improving cell therapy expansion through enhancing the quality and quantity of T cells and offering a feeder-free soluble activator for NK cell activation and expansion. This collaboration not only focuses on simplifying workflows but also aims to enhance immune cell manufacturing processes.
According to Curtis Hodge, co-founder and CEO of Nanotein, the partnership with Sartorius Stedim Biotech will grant customers access to cutting-edge tools that streamline workflows and enhance immune cell manufacturing. René Fáber, CEO of Sartorius Stedim Biotech, highlighted that this collaboration with Nanotein will empower cell therapy manufacturers to innovate more swiftly and confidently, from the early stages of process development to clinical application. The joint efforts between Sartorius Stedim Biotech and Nanotein Technologies will extend to leveraging the NanoSpark platform to create novel products catering to the rapidly growing cell and gene therapy markets.
In addition to the current offerings, Sartorius Stedim Biotech and Nanotein Technologies will work together to develop new products utilizing the NanoSpark platform, targeting the expanding cell and gene therapy sectors. This collaboration signifies a strategic move to address the evolving needs of the cell therapy industry and drive innovation in immune cell manufacturing processes. By leveraging Nanotein’s innovative technologies and Sartorius Stedim Biotech’s expertise in bioprocessing, the partnership aims to bring forth solutions that enhance the efficiency and effectiveness of cell therapy manufacturing processes.
Key Takeaways:
– The partnership between Sartorius Stedim Biotech and Nanotein Technologies aims to enhance cell therapy manufacturing by offering innovative solutions to streamline workflows and improve immune cell expansion.
– Nanotein’s NanoSpark platform, with products like the STEM-T Soluble T Cell Activator and GROW-NK Soluble Activator, addresses challenges in cell therapy manufacturing, such as inconsistent yields and reliance on feeder cells.
– The collaboration between the two companies will not only provide customers access to cutting-edge tools but also drive innovation in the cell and gene therapy markets.
– By combining Nanotein’s novel technologies with Sartorius Stedim Biotech’s bioprocessing expertise, the partnership seeks to accelerate the development of advanced solutions for immune cell manufacturing in the biotech industry.
Tags: biotech, cell therapies, process development, cell therapy, gene therapy
Read more on genengnews.com